John D Pauling

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3732992/john-d-pauling-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77	889	19	27
papers	citations	h-index	g-index
94 ext. papers	1,261 ext. citations	4.2 avg, IF	4.9 L-index

#	Paper	IF	Citations
77	Ultrasound and elastography in the assessment of skin involvement in systemic sclerosis: A systematic literature review focusing on validation and standardization <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 52, 151954	5.3	2
76	Epidemiology of systemic sclerosis in the UK: an analysis of the Clinical Practice Research Datalink. <i>Rheumatology</i> , 2021 , 60, 2688-2696	3.9	2
75	Systemic sclerosis: what's in a name?. Lancet Rheumatology, The, 2021 , 3, e820-e821	14.2	
74	Raynaud Phenomenon. In Clinical Practice, 2021, 67-77	О	
73	Impact of Covid-19 on clinical care and lived experience of systemic sclerosis: An international survey from EURORDIS-Rare Diseases Europe <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 133-138	2.3	3
72	Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol. <i>BMJ Open</i> , 2021 , 11, e044765	3	2
71	Lindsay's Nails in Early Limited Cutaneous Systemic Sclerosis With Severe Digital Vasculopathy. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1004	9.5	O
70	Factors Influencing Patient Decision-Making Concerning Treatment Escalation in Raynaud's Phenomenon Secondary to Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2021 , 73, 1845-1852	4.7	1
69	Effect of Coping Strategies on Patient and Physician Perceptions of Disease Severity and Disability in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021 , 48, 1569-1573	4.1	O
68	Developing a core set of outcome measure domains to study Raynaud's phenomenon and digital ulcers in systemic sclerosis: Report from OMERACT 2020. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 640-643	5.3	2
67	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 66-76	2.3	2
66	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. <i>Rheumatology</i> , 2021 , 60, 1410-1418	3.9	6
65	High-frequency Ultrasound Assessment of Systemic Sclerosis Skin Involvement: Intraobserver Repeatability and Relationship With Clinician Assessment and Dermal Collagen Content. <i>Journal of Rheumatology</i> , 2021 , 48, 867-876	4.1	6
64	Anti-phospholipid syndrome leading to digital ischaemia and rare organ complications in systemic sclerosis and related disorders. <i>Clinical Rheumatology</i> , 2021 , 40, 2457-2465	3.9	1
63	How do patients define Raynaud's phenomenon? Differences between primary and secondary disease. <i>Clinical Rheumatology</i> , 2021 , 40, 1611-1616	3.9	3
62	Patient perceptions of health-related quality of life in giant cell arteritis: international development of a disease-specific patient-reported outcome measure. <i>Rheumatology</i> , 2021 , 60, 4671-4	1638	3
61	A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021 , 35, 101707	5.3	2

(2020-2021)

60	The aetiopathogenic significance, clinical relevance and therapeutic implications of vasculopathy in idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2021 , 60, 1593-1607	3.9	2
59	Fulminant immune-mediated necrotising myopathy (IMNM) mimicking myocardial infarction with non-obstructive coronary arteries (MINOCA). <i>BMJ Case Reports</i> , 2020 , 13,	0.9	1
58	Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1049-1058	9.5	19
57	Performance of laser-derived imaging for assessing digital perfusion in clinical trials of systemic sclerosis-related digital vasculopathy: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1114-1130	5.3	3
56	Patient experiences of digital ulcer development and evolution in systemic sclerosis. <i>Rheumatology</i> , 2020 , 59, 2156-2158	3.9	7
55	Raynaud phenomenon and digital ulcers in systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 208-221	8.1	49
54	Gender-related differences in systemic sclerosis. <i>Autoimmunity Reviews</i> , 2020 , 19, 102494	13.6	20
53	The clinicoserological spectrum of inflammatory myopathy in the context of systemic sclerosis and systemic lupus erythematosus. <i>Indian Journal of Rheumatology</i> , 2020 , 15, 81-90	0.5	4
52	Evaluation of a patient self-stratification methodology to identify those in need of shielding during COVID-19. <i>Clinical Medicine</i> , 2020 , 20, e212-e214	1.9	1
51	Differing commissioning arrangements may contribute to geographic variation in clinical management of digital ulcers in systemic sclerosis. <i>Clinical Medicine</i> , 2020 , 20, 343-345	1.9	1
50	Treatment efficacy in secondary Raynaud's phenomenon. Lancet Rheumatology, The, 2020, 2, e132	14.2	1
49	Increased number of cases of giant cell arteritis and higher rates of ophthalmic involvement during the era of COVID-19. <i>Rheumatology Advances in Practice</i> , 2020 , 4, rkaa067	1.1	7
48	Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA. <i>Rheumatology</i> , 2020 , 59, 1709-1714	3.9	2
47	Multicenter Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2020 , 72, 723-733	4.7	14
46	Patient-reported outcome instruments in clinical trials of systemic sclerosis <i>Journal of Scleroderma</i> and Related Disorders, 2020 , 5, 90-102	2.3	8
45	Multidisciplinary collaboration among young specialists: results of an international survey by the emerging EULAR network and other young organisations. <i>RMD Open</i> , 2020 , 6,	5.9	4
44	What narrative devices do people with systemic sclerosis use to describe the experience of pain from digital ulcers: a multicentre focus group study at UK scleroderma centres. <i>BMJ Open</i> , 2020 , 10, e03	3 ³ 568	3
43	The prognostic value of cardiopulmonary exercise testing in interstitial lung disease: a systematic review. <i>ERJ Open Research</i> , 2020 , 6,	3.5	4

42	Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. <i>Rheumatology</i> , 2019 , 58, 2162-2169	3.9	17
41	Insight into the Contrasting Findings of Therapeutic Trials of Digital Ischaemic Manifestations of Systemic Sclerosis. <i>Current Treatment Options in Rheumatology</i> , 2019 , 5, 85-103	1.3	6
40	Factors Influencing Raynaud Condition Score Diary Outcomes in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2019 , 46, 1326-1334	4.1	15
39	Exploring the patient experience of digital ulcers in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 888-894	5.3	19
38	An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups. <i>Journal of Scleroderma and Related Disorders</i> , 2019 , 4, 17-27	2.3	10
37	Raynaud's phenomenon-an update on diagnosis, classification and management. <i>Clinical Rheumatology</i> , 2019 , 38, 3317-3330	3.9	32
36	Pauling and Frech reply. Journal of Rheumatology, 2019, 46, 1544-1545	4.1	
35	EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. <i>RMD Open</i> , 2019 , 5, e001014	5.9	37
34	Evolving Symptom Characteristics of Raynaud's Phenomenon in Systemic Sclerosis and Their Association With Physician and Patient-Reported Assessments of Disease Severity. <i>Arthritis Care and Research</i> , 2019 , 71, 1119-1126	4.7	15
33	Gender stratified adjustment of the DAS28-CRP improves inter-score agreement with the DAS28-ESR in rheumatoid arthritis. <i>Rheumatology</i> , 2019 , 58, 831-835	3.9	3
32	Patient organisation-led initiatives can play an important role in raising awareness about Raynaud's phenomenon and encourage earlier healthcare utilisation for high-risk groups. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 439-441	2.4	9
31	The efficacy of dietary intervention on gastrointestinal involvement in systemic sclerosis: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 112-118	5.3	9
30	The patient experience of Raynaud's phenomenon in systemic sclerosis. <i>Rheumatology</i> , 2019 , 58, 18-26	3.9	26
29	A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud's Phenomenon. <i>Arthritis and Rheumatology</i> , 2018 , 70, 903-911	9.5	39
28	Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2018 , 70, 1373-1384	4.7	38
27	Qualitative Methods to Advance Care, Diagnosis, and Therapy in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2018 , 44, 267-284	2.4	4
26	The challenge of establishing treatment efficacy for cutaneous vascular manifestations of systemic sclerosis. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 431-442	5.1	6
25	Does nailfold capillaroscopy help predict future outcomes in systemic sclerosis? A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 48, 482-494	5.3	32

(2015-2018)

24	Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis. <i>Rheumatology</i> , 2018 , 57, 712-717	3.9	26
23	Patient Perceptions of the Raynaud's Condition Score Diary Provide Insight Into Its Performance in Clinical Trials of Raynaud's Phenomenon: Comment on the Article by Denton et al. <i>Arthritis and Rheumatology</i> , 2018 , 70, 973-974	9.5	13
22	VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	42
21	O16 A study examining the reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: challenges and insights for future clinical trial design. <i>Rheumatology</i> , 2018 , 57,	3.9	1
20	Behaviour change interventions for the management of Raynaud's phenomenon: a systematic literature review. <i>BMJ Open</i> , 2018 , 8, e024528	3	5
19	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report. <i>Journal of Scleroderma and Related Disorders</i> , 2018 , 3, 249-252	2.3	25
18	Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial design. <i>Journal of Scleroderma and Related Disorders</i> , 2018 , 3, 170-174	2.3	21
17	Vasodilation is not the only approach to the management of cutaneous ulceration in systemic sclerosis. <i>Rheumatology</i> , 2017 , 56, 1559	3.9	4
16	Behaviour change interventions for the management of Raynaud's phenomenon: a systematic review protocol. <i>BMJ Open</i> , 2017 , 7, e017039	3	1
15	Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. <i>Rheumatology</i> , 2017 , 56, 912-921	3.9	47
14	Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor. <i>Arthritis Care and Research</i> , 2017 , 69, 783-793	4.7	25
13	Could nailfold videocapillaroscopy usher in a new era of preventative disease-modifying therapeutic intervention in systemic sclerosis?. <i>Rheumatology</i> , 2017 , 56, 1053-1055	3.9	O
12	Patient participation in patient-reported outcome instrument development in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 106, 184-192	2.2	7
11	Symptoms of Raynaud's phenomenon (RP) in fibromyalgia syndrome are similar to those reported in primary RP despite differences in objective assessment of digital microvascular function and morphology. <i>Rheumatology International</i> , 2016 , 36, 1371-7	3.6	11
10	Sublingual Abnormalities in Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2016 , 22, 19-21	1.1	10
9	Use of Laser Speckle Contrast Imaging to Assess Digital Microvascular Function in Primary Raynaud Phenomenon and Systemic Sclerosis: A Comparison Using the Raynaud Condition Score Diary. Journal of Rheumatology, 2015 , 42, 1163-8	4.1	35
8	Non-invasive Methods of Assessing Raynaud∃ Phenomenon 2015 , 199-242		1
7	Autoantibodies in Raynaud Phenomenon 2015 , 253-266		1

6	Mortality in systemic sclerosis-a single centre study from the UK. Clinical Rheumatology, 2013, 32, 1533-	-9 3.9	37
5	Evaluating factors influencing screening for pulmonary hypertension in systemic sclerosis: does disparity between available guidelines influence clinical practice?. <i>Clinical Rheumatology</i> , 2012 , 31, 357-	·6 ³ 1 ⁹	4
4	Predictors of health-related quality of life and fatigue in systemic sclerosis: evaluation of the EuroQol-5D and FACIT-F assessment tools. <i>Clinical Rheumatology</i> , 2012 , 31, 1215-22	3.9	28
3	The Clinical Aspects of Autoantibodies 2012 , 209-225		3
2	Use of infrared thermography as an endpoint in therapeutic trials of Raynaud's phenomenon and systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2012 , 30, S103-15	2.2	27
1	Vacuum-assisted closure therapy: a novel treatment for wound healing in systemic sclerosis. Rheumatology, 2011 , 50, 420-2	3.9	5